Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 30;18(5):2078626.
doi: 10.1080/21645515.2022.2078626. Epub 2022 Jul 19.

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years

Ivette Maldonado  1 , Manuel Plata  2 , Mauricio Gonzalez  3 , Alfonso Correa  4 , Claudia Nossa  5 , Anna R Giuliano  6 , Elmar A Joura  7 , Alex Ferenczy  8 , Brigitte M Ronnett  9 , Mark H Stoler  10 , Hao Jin Zhou  11 , Amita Joshi  11 , Rituparna Das  11 , Oliver Bautista  11 , Thomas Group  11 , Alain Luxembourg  11 , Alfred Saah  11 , Ulrike Kirsten Buchwald  11
Affiliations

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years

Ivette Maldonado et al. Hum Vaccin Immunother. .

Abstract

Among women aged 27-45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccine was also generally well tolerated and highly immunogenic in men aged 27-45 years who participated in the single-cohort mid-adult male (MAM) study (NCT01432574; n = 150). Here, we report results of a long-term follow up (LTFU) extension of FUTURE III with up to 10 years follow-up. To understand the relevance of the mid-adult women LTFU study in the context of mid-adult men vaccination, we report results from post-hoc, cross-study immunogenicity analyses conducted to compare immunogenicity (geometric mean titers; GMTs) at 1-month post-qHPV vaccine dose 3 in women and men aged 27-45 years versus women and men aged 16-26 years from prior efficacy studies. The qHPV vaccine demonstrated durable protection against the combined endpoint of HPV6/11/16/18-related high-grade cervical dysplasia and genital warts up to 10 years (median 8.9) post-dose 3 and sustained HPV6/11/16/18 antibody responses through approximately 10 years in women aged 27-45 years. Efficacy of qHPV vaccine in men aged 27-45 years was inferred based on the cross-study analysis of qHPV vaccine immunogenicity demonstrating non-inferior HPV6/11/16/18 antibody responses in men aged 27-45 years versus 16-26 years. In conclusion, durable effectiveness of the qHPV vaccine was demonstrated in women 27-45 years of age, and vaccine efficacy was inferred in men 27-45 years of age based on the serological results.

Keywords: clinical trial; effectiveness; human papillomavirus; immunogenicity; mid-adult persons; qHPV vaccine.

PubMed Disclaimer

Conflict of interest statement

IM: Ivette Maldonado has received grants through her institutions for board membership and study conduct.

MP: Manuel Plata has received grants through his institutions for study conduct and support for travel. He has also received honoraria from the Fundación Cardioinfantil.

MG: Mauricio Gonzalez has grants via his institution to serve as an investigator and colposcopist of FUTURE III study (Protocol 019).

AC: Alfonso Correa has no interests to declare.

CN: Claudia Nossa has no interests to declare.

AG: Anna R. Giuliano reports grant support from, and is an advisory board member for, Merck & Co., Inc.

EJ: Elmar Joura reports grants from Merck during the conduct of the study and personal fees from Merck Sharp & Dohme (MSD) outside the submitted work.

AF: Alex Ferenczy received consultation fees from MSD as a member of the Pathology Panel.

BR: Brigitte M. Ronnett is a consultant for MSD as part of the Pathology Panel.

MS: Mark H. Stoler has received personal fees from MSD, Roche, Becton Dickinson, and Inovio Pharmaceuticals as a consultant, all outside of the submitted work.

HJZ: Hao Jin Zhou is a former employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

AJ: Amita Joshi is a former employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

RD: Rita Das is a former employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

OB: Oliver Bautista is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

TG: Thomas Group is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

AL: Alain Luxembourg is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

AS: Alfred Saah is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

UB: Ulrike Buchwald is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may own stock/stock options in the Company.

Figures

Figure 1.
Figure 1.
Study design of FUTURE III LTFU. Catch-up vaccination was approximately 5 years after base study Day 1. Participant numbers (n) for the base study and LTFU period refer to participants vaccinated and entering LTFU, respectively (women aged 24–45 years).
Figure 2.
Figure 2.
Longitudinal anti-HPV6/11/16,/18 cLIA GMTs among LTFU-study participants who received qHPV vaccine at age 27–45 years in the FUTURE III Base study (PPI population).
See this image and copyright information in PMC

References

    1. McClung NM, Gargano JW, Park IU, Whitney E, Abdullah N, Ehlers S, Bennett NM, Scahill M, Niccolai LM, Brackney M, et al. Estimated number of cases of high-grade cervical lesions diagnosed among women — United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep. 2019;68:337–10. doi:10.15585/mmwr.mm6815a1. - DOI - PMC - PubMed
    1. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377:932–40. doi:10.1016/S0140-6736(10)62342-2. - DOI - PMC - PubMed
    1. Lu B, Viscidi RP, Wu Y, Lee JH, Nyitray AG, Villa LL, Lazcano-Ponce E, da Silva RJC, Baggio ML, Quiterio M, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res. 2012;72:676–85. doi:10.1158/0008-5472.CAN-11-0751. - DOI - PMC - PubMed
    1. Giuliano AR, Sirak B, Abrahamsen M, Silva RJC, Baggio ML, Galan L, Cintra RC, Lazcano-Ponce E, Villa LL.. Genital wart recurrence among men residing in Brazil, Mexico, and the United States. J Infect Dis. 2019;219(5):703–10. doi:10.1093/infdis/jiy533. - DOI - PMC - PubMed
    1. Beachler DC, Pinto LA, Kemp TJ, Nyitray AG, Hildesheim A, Viscidi R, Schussler J, Kreimer AR, Giuliano AR. An examination of HPV16 natural immunity in men who have sex with men (MSM) in the HPV in men (HIM) study. Cancer Epidemiol Biomarkers Prev. 2018;27:496–502. doi:10.1158/1055-9965.EPI-17-0853. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources